Login / Signup

A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes.

Stephen C BainM FeherM FisherNick HexK C S LeeJ MahonD Russell-JonesH SchouEmma G WilmotM Baxter
Published in: Diabetic medicine : a journal of the British Diabetic Association (2019)
In NG17, comparisons of basal insulins were based solely on efficacy of glycaemic control. Many of the trials used in this analysis were treat-to-target, which minimize differences in HbA1c . In the NMAs, statistical significance was severely undermined by the wide credible intervals. Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations.
Keyphrases
  • type diabetes
  • glycemic control
  • clinical practice
  • cardiovascular disease
  • insulin resistance
  • metabolic syndrome